In today’s briefing:
- Growth of SHEIN, Temu Appears to Be Boosting Asia-US Air Cargo Volume & Pricing
- China Healthcare Weekly (Jun16)-WuXi Get A “Reprieve”, Vaccine Company in Trouble, Insurance Surplus
- 4Paradigm: Sage AI Platform 5.0. Could Drive ~30% Y/Y Revenue Growth in 2024, PT Raised To HK$100
- ECM Weekly (17th June 2024)-Shift Up, Webtoon, Quantum, Guzman, MaoGeping, Johor Plant, Telix, Atour
- China Consumption Weekly (17 Jun 2024): BYD, Geely, Zeekr, Zhihu, China Literature, Tencent
- China CRSC (3969 HK): Well Worth the Premium
- Ascentage Pharma (6855.HK) Signs $1.3B Deal with Takeda – Finally on the Right Path
- Pre-IPO Fangzhou Inc. (PHIP Updates) – Some Points Worth the Attention
- Harvesting Seasonality in Iron Ore Prices Induced by Weather, Inventory Restocking, and Holidays
- Morning Views Asia: Bharti Airtel, China Vanke , Nickel Industries
Growth of SHEIN, Temu Appears to Be Boosting Asia-US Air Cargo Volume & Pricing
- For first time since 2022, carriers’ cargo revenue, yield, load factor all rising
- Asia outbound, US inbound air cargo tons both improving in early 2024
- SHEIN, Temu could account for 40%+ of US inbound air tons from CH, HK, TW
China Healthcare Weekly (Jun16)-WuXi Get A “Reprieve”, Vaccine Company in Trouble, Insurance Surplus
- Due to increasing competition/price reduction/overcapacity issue, outlook of domestic vaccine companies isn’t optimistic, which has been reflected in 24Q1 results. However, there’s also a “special one” that deserves investors’ attention.
- The status of medical insurance funds is improving rather than deteriorating, but we’re currently in the first half of the decade with the highest pressure on medical insurance.
- As the H.R.8333 proposal faced obstacles in the process of being included in NDAA, WuXi AppTec/WuXi Bio’s shares once rebounded.We remain conservative as situation is not as simple as imagined.
4Paradigm: Sage AI Platform 5.0. Could Drive ~30% Y/Y Revenue Growth in 2024, PT Raised To HK$100
- 4Paradigm, China’s AI software company with focus on enterprise-level solutions, performed well and achieved solid growth in 2023 and Q1 2024.
- In my insight, I discuss valuation framework for comparable company analysis and set a new 12-month PT for 4Paradigm.
- The company’s management has set a clear goal of profitability. I like 4Paradigm’s leadership position and hyper-growth in revenue from the Sage AI Platform.
ECM Weekly (17th June 2024)-Shift Up, Webtoon, Quantum, Guzman, MaoGeping, Johor Plant, Telix, Atour
- Aequitas Research’s weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
- On the IPO front, we continued to look at Shift Up (462870 KS), Guzman Y Gomez and Webtoon Entertainment (WBTN US), along with Mao Geping Cosmetics.
- On the placement front, there were quite a few deals in India, while Atour Lifestyle Holdings (ATAT US) was the major Asia linked offerings.
China Consumption Weekly (17 Jun 2024): BYD, Geely, Zeekr, Zhihu, China Literature, Tencent
- European Commission will impose provisional tariffs on imported Chinese battery electric vehicles.
- Zeekr’s deliveries increased by 117% YoY in 1Q24 and by 112% YoY in the first five months of 2024.
- Ant Group will pay RMB1 billion to sponsor content creators on AliPay.
China CRSC (3969 HK): Well Worth the Premium
- China Railway Signal & Communication (3969 HK)‘s latest order backlog is estimated to be Rmb173.7bn, enough to cover FY24F revenue by 4.4x.
- Gross margin has sustained expansion, reaching a record high of 27.8% in 1Q24. Higher R&D expenses will benefit its medium-term earnings.
- Net cash equals 59% of the share price, allowing it to maintain over 50% payout and potentially higher going forward. Operating cash flow has also turned around to positive.
Ascentage Pharma (6855.HK) Signs $1.3B Deal with Takeda – Finally on the Right Path
- Ascentage was originally in an extremely difficult situation, but the cooperation with Takeda turned things around. Ascentage has obtained urgently needed cash flow to solve the survival problem.
- At this stage, it’s possible for Ascentage to hit about 50% market value of HCM. Investors are interested to know if APG-2575 would also be out-licensed, which however is not easy.
- Ascentage’s current strength isn’t sufficient to self-build sales system. While this deal is a good start, if Ascentage still chooses to do commercialization on its own, it’s time to sell.
Pre-IPO Fangzhou Inc. (PHIP Updates) – Some Points Worth the Attention
- Fangzhou cannot get around the decreasing unit-price of drugs and the increasing role of medical insurance in chronic-disease treatment.It’s challenging to find patients willing to pay out of own pockets.
- The internal dispute between the Founder and shareholders hasn’t ended, and related litigation is still pending. This makes us concerned about the stability of future business development and corporate governance.
- Fangzhou has significant cash flow pressure. In the case of increasingly fierce competition in the industry, without successful business diversification/transformation, growth prospects is gloomy, Valuation should be lower than peers.
Harvesting Seasonality in Iron Ore Prices Induced by Weather, Inventory Restocking, and Holidays
- SGX Iron Ore prices exhibit seasonality. For select six months being long Iron Ore combined with short positions during other months deliver positive P&L based on back tests.
- In line with prices, realised volatility exhibits seasonality too. Options strategies can exploit this to deliver superior alpha & higher sharpe ratio.
- Averages confound extreme variances. Monthly iron ore futures price returns are less volatile during the months of December, February, June, October, & March based on range.
Morning Views Asia: Bharti Airtel, China Vanke , Nickel Industries
Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.